Search our Site. Find Results Fast.
Search this site
260 results found with an empty search
Other Pages (65)
- Finances | Shwachman-Diamond Syndrome Alliance
Our philosophy, commitment, and financial reports are posted here. Finances Finances Shwachman-Diamond Syndrome Alliance is a US-based nonprofit 501(3)c corporation, serving the global SDS community. Our EIN and IRS determination letter is available, here . 100% of your donation goes into an account dedicated solely to research and therapy development. We pride ourselves on maximizing the impact on SDS patients' and families' lives through running a professional, sustainable, and efficient nonprofit research organization with dedicated, passionate staff. All our operation expenses, including staff compensations, are covered by a separate account with funding from sources such as grants and private dedicated donors. Every single penny of YOUR donation — community donations and fundraisers — goes specifically towards SDS research and therapy development. We choose the best route for each research and therapy development program. Some are led in-house, some in partnership with research institutions, and some with specialized service providers such as contract research organizations (CROs). In every case, the goal is the same: the greatest impact for the SDS community, as efficiently as possible. We are working to make disease-modifying SDS clinical trials a reality by 2030, so SDS families have more birthdays to celebrate. See it in action on our strategy and roadmap page . Our leadership team works highly strategically to ensure that your donation leads to a much bigger impact — bigger than the amount of the donation itself can fund. How do we do that? We use your donation to create preliminary results, critical research tools, and infrastructure, and use them to (1) enable more research and to accelerate them, and (2) to get much bigger grants, from the governmental funding agencies, private foundations, or industry sposors. This strategy continues to supercharge our progress. Further, our leadership team has the expertise to attract world-class partners to put up their own funding for our project — the mouse model project with The Jackson Laboratory being a prime example. Documents IRS Form 990 FY 2025 Form 990 Filing FY 2023 Form 990 Filing FY 2022 Form 990 Filing FY 2021 Form 990 Filing FY 2020 Form 990-N Other Documents US State Registration Disclosures
- Strategy & Roadmap | SDS Alliance
The SDS Alliance understands how rare disease research is most efficiently conducted. Instead of passively soliciting researchers for ideas,we are actively identifiying projects that are key to therapy development, seeks out the best experts to do the work, and coordinates the efforts to deliver results. The investments we make are highly strategic and aimed at leveraging NIH grants and enabling additional projects. Let's #CureSDS together. Strategy & Roadmap Collaboration is not enough. Therapy development needs coordination to achieve results. That's how we drive progress, together. Unlike foundations in the past, we understand how rare disease research is most efficiently conducted. Instead of passively soliciting researchers for ideas or funding a favorite without a plan or proper agreements, we invest strategically. We actively identify projects that are key to SDS therapy development, find the best experts to do the work, and coordinate the efforts to deliver results. Our goal is to begin disease-modifying clinical trials for SDS by 2030, so SDS families have more birthdays to celebrate. We value your donations more than the face value, as we know it's personal. We invest only in critical projects that have the potential to accelerate therapy development and leverage large NIH grants and other funding whenever possible. For example, our mouse project is leveraging substantial NIH funding through the Jackson Laboratory and will provide a critical tool for a wide range of therapy development projects. We believe that this strategy is the most effective way to generate results that matter to us, the patient community. Quick Video overview of WHAT we do and WHY. Timeline of impact your support made possible Pipeline of Therapies for Shwachman-Diamond Syndrome. The Programs We Follow and Support. Your support has impact . See the progress with timelines and costs. Our SDS therapy development roadmap includes a wide range of initiatives and projects driven by us, with your support. We welcome researchers, patient advocates and organizations, and biotech companies to join our efforts toward developing therapies for SDS. This is a living document that we update and refine regularly. Costs and timelines are estimates. MOUSE AND OTHER PRECLINICAL MODELS – ACTIVE Goal: a mouse and/or other models that reflect the genetics of human SDS and reproduce SDS phenotypes, to enable therapy development based on various strategies, such as gene-targeted approaches, small molecules, and drug repurposing. Programs/Activities: ACTIVE The initial focus is a mouse model humanized with the splice site mutation and flanking regions. Status: Mouse model development launched , meet the development team , phase 1 complete ACTIVE A pilot study for an alternative mouse model project has launched. Time frame: 1-2 years for building and initial characterization, 3-4 years for characterization of malignancy predisposition Cost: $300,000 ($150,000 covered by The Jackson Laboratory/NIH funding) iPSC AND OTHER PATIENT DERIVED CELL LINES (BIOBANK) – EXPANDING Goal: Patient cell lines available to researchers anywhere in the world, to test and develop various SDS therapies. Programs/Activities: LIVE Cell line types include Lymphoblastoid Cell Lines (LCLs), fibroblasts, and Induced Pluripotent Stem Cells (iPSCs). De-identified clinical information associated with the samples. Samples are processed, stored, and distributed by the Coriell Institute. Goal of 25-50 patients enrolling, covering various ethnic backgrounds, and the whole range of SDS mutations. Status: SDS Cell Biobank pilot complete, SDS Cell Biobank launched, iPSCs development launched , isogenic pair created Time frame: 2-4 years Cost: $150,000 (Leveraging $75,000 covered by Coriell Institute/NIH funding, and a grant from UPenn ODC) GLOBAL DATABASE / PATIENT DATA HUB – ACTIVE Goal: Critical for determining therapeutic endpoints for clinical trials; Global participation and access to data Programs/Activities: LIVE Survey Platform for patient-reported data and collaboration: SDS-GPS Genotype/phenotype correlation and identification of new SDS genes and mutations using Whole Exome and Whole Genome Sequencing (WES/WGS) LIVE Diagnostics support for patients (through cost assistance, a global network of knowledgeable physicians, and inclusion of SDS on all relevant panels). Get tested! Cost: $100,000 per year (leveraging grants; $10,000 diagnostics support covered by charity partners) NETWORK DEVELOPMENT AND CLINICAL TRIAL READINESS – IN PROGRESS Goal: Facilitating clinical trial planning, initiation, and regulatory agency engagement Programs/Activities: Obtaining and promoting ICD-10 (and ICD-11) codes for SDS. LIVE Our ICD-10 code application in the US has been successful and approved by the CDC. See Press Release and ICD Resource Page Engaging with regulatory agencies (i.e. FDA) DONE FDA CBER OTAT Patient-Focused Drug Development Listening Meeting Two additional meetings were completed in 2024 DONE MAJOR EVENT: EL-PFDD for Shwachman-Diamond Syndrome conducted on June 4, 2025 . Continued patient community and research network building LIVE Patient-focused educational resources, including research updates (Ask an Expert webinars), blog posts , website resources, conferences (SDS POPS) , and more) LIVE Patient community connections (Monthly Community Coffee Chat , closed Facebook groups, and more) LAUNCHED Project PACER to build capacity for CER for SDS . Time frame: 2-3 years to build, then ongoing Cost: $100,000 (leveraging grants, PCORI, and industry funding) GENE TARGETED THERAPY DISCOVERY AND DEVELOPMENT – ACTIVE Goal: Getting pre-clinical work ready for translation into clinical application (therapies for patients) ACTIVE Gene editing, base editing, prime editing. Testing and optimizing lead candidates on mouse model from above. (Drs. Brendel and Bauer at Boston Children's Hospital, USA) IN PROGRESS Stop-codon read-through / nonsense suppression (Drs. Cipolli and Bezzerri, Verona, Italy) PAUSED Antisense Oligonucleotide Therapies (ASOs) and other RNA-based therapies. Discovery, testing, and optimizing of lead candidates on mouse model from above. Time-frame: 3-5 years (from discovery to pre-clinical and proof-of-concept work) $2 million (funded in large part by the Principal Investigators (PI) through NIH funding and biopharma industry) DRUG DISCOVERY AND DEVELOPMENT – IN PROGRESS Goal: Getting pre-clinical work ready for translation into clinical application ( therapies for patients) PAUSED Small-molecule screening to find compounds that counteract the ribosome assembly defect in SDS. Test and optimize lead candidates on the mouse model from above. (Dr. Allan Warren, Cambridge, UK) PLANNING Drug repurposing (high-throughput screening). Test and optimize lead candidates on the mouse model from above. IN PROGRESS Collaboration with EveryCure includes SDS in its screen. Time frame: 3-5 years (from discovery to pre-clinical and proof-of-concept work) $2 million (funded in large part by the Principal Investigators (PI) through NIH funding and venture capital) NEW TARGET IDENTIFICATION – PLANNING Identifying additional downstream targets using proteomics and other -omics 2-4 years $500,000 (leveraging NIH and industry funding) PHASE I (DRUG) CLINICAL TRIAL 1-2 years $1 million (leveraging NIH and industry funding) PHASE II (PILOT) CLINICAL TRIAL 1-2 years $5 million (leveraging NIH and industry funding) PHASE III CLINICAL TRIAL 3-5 years $10 million (leveraging industry funding) Why do we need models for SDS? Model systems, such as mouse models, are developed to replicate a disease in an organism other than humans. That way, researchers can investigate various aspects of disease without having to burden a human patient. Different research questions need different types of models, from yeast cells to worms to flies to mice and more. For therapy development, we need a model system that is as close as possible to humans but is practical to work with in order to save time. Mouse models have become the gold standard in research. Unfortunately, developing a mouse model for SDS has proven historically difficult, because the gene responsible for most cases of SDS, SBDS, is essential. Mice with too little SBDS are not viable, and mice with some have no SDS symptoms (phenotype). As one of our first major projects, we set out to try all options to create a mouse model for SDS. This work is still ongoing and we are committed to leaving no stone unturned. Roadmap to Therapies and Cures for SDS 1. Build humanized mouse and other SDS models that has the most common and relevant human mutation is viable and shows relevant phenotypes designed for testing a wide range of therapeutics 2. Characterize the models how does the humanized gene behave in the model what symptoms can be observed (what, when, where) develop measurable biomarkers for testing therapies 3. Test and optimize therapies on the model gene editing, base editing, and prime editing therapies antisense oligonucleotide (ASO) and other RNA therapies small molecules and repurposed drugs 4. Safety and Efficacy Studies test efficacy and safety of discoveries on suitable models to prepare for clinical trials 5. Patient Clinical Trials present results of model work to the FDA and international regulatory agencies to proceed with clinical trials in human patients seek FDA and international approval Goal: SDS Therapies and Cures
- Welcome to the Shwachman-Diamond Syndrome Alliance - SDS Alliance
Shwachman-Diamond Syndrome Alliance (SDS Alliance) is a 501(3)c public nonprofit foundation/organization, focused on improving patients' lives by accelerating research, fostering international collaborations, and providing quality educational and awareness materials. Shwachman-Diamond Syndrome is a life-threatening condition. We save lives by accelerating research to #CureSDS. Join our network of patients, families, doctors, and researchers, working together to drive research and accelerate therapy development, so that people with Shwachman-Diamond Syndrome can live their lives to their full potential and get more birthdays to celebrate. Join Us Meet the Team Our Story We bring patients, caregivers, doctors, and researchers together to drive research and accelerate therapy development. As a patient advocacy nonprofit, we build and share research tools and infrastructure, amplify the patient voice to guide therapy development, create collaboration frameworks and opportunities, and strategically invest funding into projects with a potential to become transformative therapies. Our Impact Join our mailing list. Be part of our Global Network. Join Now Be the first to learn about updates on SDS research, care guidelines, therapy development, advocacy, and community news. Developing a therapy for SDS is complex, expensive, and never fast enough . Our programs are designed to get it done . Now. Our Strategy For Patients and Families For Doctors and HCPs For Researchers and Industry Amazing Opportunity to Be Heard: SDS PFDD Meeting We hosted an Externally-Led Patient-Focused Drug Development Program (EL-PFDD) meeting for Shwachman-Diamond Syndrome on June 4th, 2025. Cinicnnatti, OH and Virtual via Zoom. Provide your thoughts today! Watch the recording and learn more See our impact . New collaborations, further reach, faster progress. Featured News All our Blogs Global SDS Action Week: Easy Actions You Can Take This Week or Anytime Global SDS Action Week runs November 1 to 7 and culminates in SDS Awareness Day on November 7. This year, we created an interactive checklist for you, with one simple action a day you can do anytime, anywhere. How a Young SDS Advocate Got November 7 Recognized as SDS Awareness Day in New Jersey Joyce, a young advocate with Shwachman-Diamond Syndrome, got November 7 recognized as SDS Awareness Day in New Jersey. Hear her story and how she did it. Joyce, a young advocate with Shwachman-Diamond Syndrome, got November 7 recognized as SDS Awareness Day in New Jersey. Hear her story and how she did it. The SDS PACER Course Is Now Live! Deep Dive into SDS, Research, and How You Can Make a Difference The SDS PACER Course is a free, self-paced online course for Shwachman-Diamond Syndrome patients and families. Six modules covering SDS science, research, and therapy development. 1 2 3 4 5 Let’s give SDS patients and their families more birthdays to celebrate. Join us. Join our global network of patients, families, doctors, and researchers, working together to drive research and accelerate therapy development, so that people with Shwachman-Diamond Syndrome can live their lives to their full potential. Join Us Donate
Blog Posts (142)
- Global SDS Action Week: Easy Actions You Can Take This Week or Anytime
Welcome to SDS Spotlight — our monthly series where Eszter shares a quick update on what we're working on, what we're excited about, and how YOU can get involved. Each month features a short video and a deeper dive right here on the blog. In this month's SDS Spotlight, Eszter Hars, Ph.D., molecular biologist, SDS Alliance CEO, and mother of a child with SDS, shares what Global SDS Action Week is about and how to take part, this week or any time. In this month's SDS Spotlight, Eszter Hars, Ph.D., introduces Global SDS Action Week and Awareness Day and invites you to take some easy actions to help move improved treatments and new therapies forward. What is Global SDS Action Week? Global SDS Action Week runs November 1 to 7 and culminates in SDS Awareness Day on November 7. This year, we created an interactive checklist for you, with one simple action a day you can do anytime, anywhere. Check off what you do. Skip what doesn't fit your life right now. Every action is optional, you can do them in any order, and you can do them anywhere in the world. Full details about the week are on our Action Week page. Why November 7? Shwachman-Diamond Syndrome got its name from a paper published in November 1964 by Drs. Shwachman and Diamond, who were practicing at Boston Children's Hospital at that time. In 2003, the gene responsible for most SDS cases was discovered and published by Dr. Rommens at Sick Kids in Canada. The gene was named SBDS, and is located on Chromosome 7 (section 11), also known as 7q11, which reads as 11.7. So the date November 11 represents the name day or birthday of SDS, and represents the whole SDS community, whatever your gene or diagnosis. The seven actions We compiled a list of seven easy actions you can take, one for each day of SDS Action Week. All serve a purpose of coming together as a community and support research and therapy develpment. Join us! Day 1 (November 1): Read the Voice of the Patient report. A year ago, our community shared what life with SDS is really like. Those words became a report that researchers, drug developers, and regulators can now read, in your own words. Read the report. Day 2 (November 2): Make SDS visible in the medical record. In the US, SDS has its own ICD-10 code, D61.02. Share it with your medical team and ask them to confirm it is in the chart. A specific code helps make SDS visible in medical records and research. Read more. Outside the US, SDS Alliance is working on the groundwork for codes in other countries and regions. If you have a medical or coding background and would like to help, email connect@sdsalliance.org. Day 3 (November 3): Add your voice to the research. Join SDS-GPS, our global survey platform, or complete the gene therapy perspectives survey. What you share helps shape research and how clinical trials are designed. Your privacy is protected. Join SDS-GPS, log in, or read about privacy. Day 4 (November 4): Start the SDS PACER Course. It is free and self-paced, with six modules that help you understand the science and take part in research discussions. It also helps prepare you to serve on research and drug development advisory boards. Start the course. Day 5 (November 5): Explore our free guides. School success, the school letter tool, and the interactive gene therapy guide are all in one place. Share one with a teacher, a doctor, or a newly diagnosed family. See all guides. Day 6 (November 6): Give. A monthly gift of any amount helps us give SDS patients and families more birthdays to celebrate, and it shows strength in numbers. Join Monthly Giving Allies. Prefer a one-time gift? Donate here. Day 7 (November 7): Share your story. Post about your life with SDS, or share one fact about it, wherever you are. To contribute more privately, find your chapter in the Essential Guide story tool. Pseudonyms are welcome. Find your chapter. US families: the checklist also has one optional bonus action. Meet Joyce Joyce is a young advocate with SDS who asked her New Jersey assemblywoman to recognize November 7 as Shwachman-Diamond Syndrome Awareness Day. Assembly Joint Resolution 119 passed the Assembly 77 to 0 and the Senate 40 to 0, and Gov. Mikie Sherrill signed it on August 6. Watch our full conversation with Joyce, and read how she did it: Interview with Joyce Joyce's story Why we are doing this Awareness is only the start. What makes a difference is what actions we take. Each of these actions connects to research, better care, or a stronger community: more voices in SDS-GPS, more families who understand the science, and more support for the work ahead. The checklist is ready anytime, so every action works whenever you are ready. Which action will you take first? Tell us on our social posts, or email us at connect@sdsalliance.org. Subscribe to our blog to get email reminders about new posts! ① Login or create an account at the top of this website ② Select Settings in the member’s menu ③ Click on Subscribe Now, and make sure blog posts are selected in the list below
- How a Young SDS Advocate Got November 7 Recognized as SDS Awareness Day in New Jersey
On August 6, 2026, Gov. Mikie Sherrill signed Assembly Joint Resolution 119, recognizing November 7 as Shwachman-Diamond Syndrome Awareness Day in New Jersey. The resolution passed the Assembly 77 to 0 and the Senate 40 to 0. Behind this milestone achievement is Joyce, a young advocate with SDS who started speaking up and sharing her SDS story when she was just 13. She brought this idea to her assemblywoman while she was still a teenager, and then saw it through every step. Today she is taking a gap semester, interning in Washington, DC, and starting at NYU in the spring to study public policy. Eszter Hars, PhD, SDS Alliance CEO, sat down with Joyce on October 30, 2026, to ask how she did it, why it matters, and what she would tell other families. Here is what we learned. Watch the full conversation Interview with Joyce about her efforts in getting SDS Awareness Day recognized in New Jersey, and her WHY. About 30 minutes. Recorded October 30, 2026. Why she made it happen Joyce had watched friends in other rare disease communities work to get awareness days for their conditions. She saw a way to do the same for SDS. That's, like, 100 new lawmakers who have never heard of the condition, who are now aware that the condition is a real thing and that real people are impacted by it. SDS affects an estimated 2,000 to 3,000 people in the US, and many doctors have never heard of it. Joyce's goal was simple: let people know the condition exists. We can't get treatment or research or funds if nobody knows that the condition exists. Why November 7 Joyce researched the history of SDS and found that the condition was first described in November 1964 in a publication by Boston Childrens' Hospital doctors Dr. Shwachman and Dr. Diamond, so she chose November. For the day, she picked the 7th, because the SBDS gene (the gene responsible for most SDS cases) is on Chromosome 7, section11 (also known as 7q11). She flipped that into 11/7 or November 7th. I wanted everyone to be able to celebrate their condition even if they weren't genetically diagnosed. That is why the date works for the whole SDS community, whatever their gene or diagnosis. The timeline for the NJ recognition of SDS Awareness Day to be established June 2025: Joyce met with Assemblywoman Linda Carter and shared the idea. The assemblywoman liked it and suggested waiting for the next legislative session to begin. January 2026: The resolution was introduced as AJR 119, with bipartisan support. May 12: Assembly committee hearing. May 18: The Assembly passed it, 77 to 0. June 11: Senate committee hearing. June 30: The Senate passed it, 40 to 0. August 6: Gov. Mikie Sherrill signed it. The resolution asks the governor to issue a proclamation each year recognizing November 7 as Shwachman-Diamond Syndrome Awareness Day. How she did it, step by step Joyce is the first to say that none of this was complicated, just slow. We still give her tremendous credit. A field trip to the State House in her AP Government class in high school showed her how a bill is introduced and sparked the idea. Here is her process: Start with your local representative. Joyce shared the idea with Assemblywoman Carter. They wrote the language together, so that every fact was correct. Introduce the resolution, then campaign for it. She called every office in the State House and asked them to cosponsor. Get leadership on board. Senate President Nick Scutari and Speaker Craig Coughlin cosponsored it. Joyce explains that leaders decide what gets scheduled, so their support helped move the resolution through hearings and votes. Share your story at the hearings. She wrote a speech and testified at both committee hearings, and she was at the State House for the votes. Repeat in the second chamber, then the governor. Be patient. She waited from June to January so that the resolution could be introduced at the start of a session, with enough time to pass both chambers. Rules and calendars differ from state to state. If you want to try this where you live, start with a conversation with your state representative. Her advice to other young people Joyce started advocating at 13 and was scared at first. I have mentored advocates as young as 6 years old, and it doesn't matter what age you are, you can get out there. You could share your story. You could contact your representative. After you do it once or even twice, … you realize how friendly these people are, how they really truly want to listen to their community. What she is pursuing next After the New Jersey resolution, Joyce shared the language with her US representative, and a federal resolution, H.Res.1133, was introduced in the House on March 24, 2026, with Reps. Tom Kean Jr. and Josh Gottheimer as sponsors. At Camp Sunshine, 46 community members signed a letter supporting it. As of November 7, 2026, it is awaiting committee review. Because a new Congress starts in January 2027, the resolution may need to be reintroduced in the next session. Joyce plans to keep going. US families who would like to help can ask their representative to cosponsor H.Res.1133. You will find a short message you can adapt in our Action Week checklist, and the full text of the resolution is on congress.gov. Joyce's advocacy for the federal resolution is her own initiative. SDS Alliance is proud to share her story and to celebrate the New Jersey recognition. More about Joyce Joyce also loves horseback riding, singing, and musical theater, and she performs in New York. She wrote and recorded a song about her SDS experience, titled "Don't Surrender to Fear", as part of the 2026 Rare Artist program from Rare Advocates. More about the song here. She is now working with a producer on a collection of new songs about the rare disease journey, with a full album planned for late 2027. Thank you Thank you, Joyce, for showing what one person with a good idea can do. Thank you to Assemblywoman Linda Carter, Senate President Nick Scutari, Speaker Craig Coughlin, and Gov. Mikie Sherrill for making November 7 official in New Jersey. Share your story, too Joyce's advice applies to all of us: your story matters, and you can share it at any age. There are many ways and opportunities to share your story and make an impact toward more research and clinical trials by 2030, so that SDS patients and families can have more birthdays to celebrate. You can share your story on our blog, on your own social media channels, in your personal network, school, or work. We are here to help with resources and guidance. If you would like to stay more private, consider contributing to our Essential Guide, and find your chapter in our story tool. Pseudonyms are welcome. How to participate in SDS Action Week and Awareness Day Check out our SDS Action Week and Awareness Day page and open the Action Week checklist for more ways to take part. Subscribe to our blog to get email reminders about new posts! ① Login or create an account at the top of this website ② Select Settings in the member’s menu ③ Click on Subscribe Now, and make sure blog posts are selected in the list below
- The SDS PACER Course Is Now Live! Deep Dive into SDS, Research, and How You Can Make a Difference
Welcome to SDS Spotlight — our monthly series where Eszter shares a quick update on what we're working on, what we're excited about, and how YOU can get involved. Each month features a short video and a deeper dive right here on the blog. In this month's SDS Spotlight, Eszter Hars, Ph.D. introduces the new SDS PACER Course and highlights additonal opportunities to accelerate research and therapy development. If you live with Shwachman-Diamond Syndrome (SDS) or care for someone who does, you already know more about life with SDS than you think. You know what it feels like to wait for a bone marrow result. You know the exhaustion of explaining SDS to yet another doctor who has never seen it before. You know which questions keep you up at night, and which ones still don't have good answers. Researchers need to hear your insights. It is not just a "nice to have." It is a critical requirement for research and therapy development that actually helps people and families like you and me. This true partnership works best when we speak the same language — when we agree on the basic concepts and feel comfortable discussing them frankly. That is why we built the SDS PACER Course. What Is the SDS PACER Course? The SDS PACER Course — Patient and Family Edition is a free, self-paced online learning series built specifically for the Shwachman-Diamond Syndrome community. Its six modules are designed to help you understand the science behind SDS well enough to participate meaningfully in discussions, research, research prioritization and design, advocacy, and the decisions around your own or your family's care. It is available now at www.sdsalliance.org/courses . Create a free account on the SDS Alliance website and log in at the top of the page, then go to My Programs. Start whenever you are ready, at your own pace, on any device. What You Will Learn The six modules build on each other, from the foundations of patient-centered research to the frontier of SDS therapy development: Module 1 — What Is Patient-Centered Research and Why Does It Matter for SDS? What patient-centered comparative effectiveness research is, how it differs from other kinds of research, and what your role in it can look like — anchored by a presentation from our collaborator Dr. Vanessa Merker of Massachusetts General Hospital and Harvard Medical School. Module 2 — Genes, Proteins, and the SBDS Gene The genetics of SDS in plain language — what genes do, what variants are, how SBDS mutations cause SDS, and what that means for diagnosis, inheritance, and research. Module 3 — Ribosomes, SBDS, and How SDS Affects the Body Why SDS affects so many different organ systems, what ribosomal stress means, and why every patient's experience is different. Module 4 — Clonal Hematopoiesis, Leukemia Risk, and the Future of Treatment What happens in the bone marrow over time in SDS, how researchers are learning to predict leukemia risk, and what that means for surveillance decisions and emerging therapies. Module 5 — Clinical Research and Therapy Development: How Treatments Reach Patients The full arc of drug development — from pre-clinical research through clinical trials and regulatory approval — and the many ways patients and organizations can shape that process. Module 6 — Stem Cell Transplant and Gene Therapy: What's Available Now and Where We Are Headed (coming next week) What HSCT is, how donor matching works, how bone marrow surveillance tools work, and the three gene therapy approaches being developed specifically for SDS — including why gene editing is a better fit than traditional gene therapy. Each module includes videos, written content, and a short quiz. You earn a badge and a certificate for each one you complete. What Will I Get Out of the Course? After completing the course, you will be equipped to make a real difference in many settings: At the doctor: Speak up more clearly and confidently for yourself or your child With researchers: Help scientists design better SDS studies with your informed perspective In the community: Help and teach other SDS families — especially the newly diagnosed In clinical trials: Make decisions about participation with real confidence On advisory boards: Provide an informed patient perspective on research planning With SDS Alliance: Participate in projects and help shape what we build next You do not need a science background. This course is written for people who have been living with SDS — not for researchers*. If you have been managing this condition, or supporting someone who has, you already have the experience. The course gives you the framework to use it. *A course dedicated to clinicians and researchers is coming soon. Built for the Community, With the Community This course was developed through Project PACER — SDS Alliance's two-year initiative funded by the Patient-Centered Outcomes Research Institute (PCORI) to build capacity for patient-centered research in Shwachman-Diamond Syndrome. Our community survey shaped the content by asking what topics matter most to you. Our co-developers — patients and caregivers who test-drove the course and provided thoughtful feedback — helped us clarify and improve the content and . They include adult patients, caregivers of children at every stage of the SDS journey, spanning three continents. When you take the course, you benefit from their work — and have the opportunity to help improve it further. Our goal is clinical trials by 2030. An informed, research-ready community is a critical piece of the puzzle. The course is how we build that together. Frequently Asked Questions Is the course free? Yes. The SDS PACER Course is completely free for all SDS community members worldwide. Do I need a science background? No. The course is written for patients and families, not scientists. Plain language throughout. How long does it take? Each module takes approximately 30–60 minutes. You can take breaks and continue anytime — the course saves your progress automatically. Who can take the course? Anyone in the SDS community — patients, caregivers, parents, partners, and family members. An edition for clinicians and researchers is coming soon. Is it available in other languages? The course is currently available in English. We are exploring additional languages as funding allows. What do I get when I finish? A badge and certificate for each completed module, and a full course certificate when all six are done. Take the SDS PACER Course Free, self-paced, open to the SDS community worldwide. Start the course at www.sdsalliance.org/courses → Create a free account or log in, go to My Programs, and begin with Module 1. Each module takes 30–60 minutes. You can take breaks and continue anytime. Questions or comments? Email us at pacer@sdsalliance.org. All October Resources at a Glance 🎓 Take the new SDS PACER course: www.sdsalliance.org/courses 🧬 New to SDS-GPS? Join here: www.sdsalliance.org/sds-gps-join 🧬 Existing SDS-GPS users, log in and complete your surveys at www.sdsalliance.org/sds-gps-login 🔬 St. Jude GeneTX study + SDS Alliance gene therapy survey: full details at https://www.sdsalliance.org/post/sds-gene-therapy-perspectives-survey 📅 SDS Action Week: November 1–7, 2026. 📞 SDS Family Network Welcome Call: Check the SDS Alliance Family Network (Facebook group) or email connect@sdsalliance.org Questions? Contact us anytime at connect@sdsalliance.org Project PACER is funded by the Patient-Centered Outcomes Research Institute (PCORI), Engagement Award EASO-42419. Subscribe to our blog to get email reminders about new posts! ① Login or create an account at the top of this website ② Select Settings in the member’s menu ③ Click on Subscribe Now, and make sure blog posts are selected in the list below











